| 1. |
- Tran, K. B., et al.
(författare)
-
The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019
- 2022
-
Ingår i: Lancet. - 0140-6736. ; 400:10352, s. 563-591
-
Tidskriftsartikel (refereegranskat)abstract
- Background Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. Findings Globally, in 2019, the risk factors included in this analysis accounted for 4.45 million (95% uncertainty interval 4.01-4.94) deaths and 105 million (95.0-116) DALYs for both sexes combined, representing 44.4% (41.3-48.4) of all cancer deaths and 42.0% (39.1-45.6) of all DALYs. There were 2.88 million (2.60-3.18) risk-attributable cancer deaths in males (50.6% [47.8-54.1] of all male cancer deaths) and 1.58 million (1.36-1.84) risk-attributable cancer deaths in females (36.3% [32.5-41.3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20.4% (12.6-28.4) and DALYs by 16.8% (8.8-25.0), with the greatest percentage increase in metabolic risks (34.7% [27.9-42.8] and 33.3% [25.8-42.0]). Interpretation The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
|
|
| 2. |
- Alvarez, E. M., et al.
(författare)
-
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019
- 2022
-
Ingår i: Lancet Oncology. - : Elsevier BV. - 1470-2045. ; 23:1, s. 27-52
-
Tidskriftsartikel (refereegranskat)abstract
- Background In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15-39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults. Methods Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15-39 years to define adolescents and young adults. Findings There were 1.19 million (95% UI 1.11-1.28) incident cancer cases and 396 000 (370 000-425 000) deaths due to cancer among people aged 15-39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59.6 [54.5-65.7] per 100 000 person-years) and high-middle SDI countries (53.2 [48.8-57.9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14.2 [12.9-15.6] per 100 000 person-years) and middle SDI (13.6 [12.6-14.8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23.5 million (21.9-25.2) DALYs to the global burden of disease, of which 2.7% (1.9-3.6) came from YLDs and 97.3% (96.4-98.1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally. Interpretation Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Murray, Christopher J. L., et al.
(författare)
-
Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
- 2018
-
Ingår i: The Lancet. - 1474-547X .- 0140-6736. ; 392:10159, s. 1995-2051
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Population estimates underpin demographic and epidemiological research and are used to track progress on numerous international indicators of health and development. To date, internationally available estimates of population and fertility, although useful, have not been produced with transparent and replicable methods and do not use standardised estimates of mortality. We present single-calendar year and single-year of age estimates of fertility and population by sex with standardised and replicable methods. Methods: We estimated population in 195 locations by single year of age and single calendar year from 1950 to 2017 with standardised and replicable methods. We based the estimates on the demographic balancing equation, with inputs of fertility, mortality, population, and migration data. Fertility data came from 7817 location-years of vital registration data, 429 surveys reporting complete birth histories, and 977 surveys and censuses reporting summary birth histories. We estimated age-specific fertility rates (ASFRs; the annual number of livebirths to women of a specified age group per 1000 women in that age group) by use of spatiotemporal Gaussian process regression and used the ASFRs to estimate total fertility rates (TFRs; the average number of children a woman would bear if she survived through the end of the reproductive age span [age 10–54 years] and experienced at each age a particular set of ASFRs observed in the year of interest). Because of sparse data, fertility at ages 10–14 years and 50–54 years was estimated from data on fertility in women aged 15–19 years and 45–49 years, through use of linear regression. Age-specific mortality data came from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 estimates. Data on population came from 1257 censuses and 761 population registry location-years and were adjusted for underenumeration and age misreporting with standard demographic methods. Migration was estimated with the GBD Bayesian demographic balancing model, after incorporating information about refugee migration into the model prior. Final population estimates used the cohort-component method of population projection, with inputs of fertility, mortality, and migration data. Population uncertainty was estimated by use of out-of-sample predictive validity testing. With these data, we estimated the trends in population by age and sex and in fertility by age between 1950 and 2017 in 195 countries and territories. Findings: From 1950 to 2017, TFRs decreased by 49·4% (95% uncertainty interval [UI] 46·4–52·0). The TFR decreased from 4·7 livebirths (4·5–4·9) to 2·4 livebirths (2·2–2·5), and the ASFR of mothers aged 10–19 years decreased from 37 livebirths (34–40) to 22 livebirths (19–24) per 1000 women. Despite reductions in the TFR, the global population has been increasing by an average of 83·8 million people per year since 1985. The global population increased by 197·2% (193·3–200·8) since 1950, from 2·6 billion (2·5–2·6) to 7·6 billion (7·4–7·9) people in 2017; much of this increase was in the proportion of the global population in south Asia and sub-Saharan Africa. The global annual rate of population growth increased between 1950 and 1964, when it peaked at 2·0%; this rate then remained nearly constant until 1970 and then decreased to 1·1% in 2017. Population growth rates in the southeast Asia, east Asia, and Oceania GBD super-region decreased from 2·5% in 1963 to 0·7% in 2017, whereas in sub-Saharan Africa, population growth rates were almost at the highest reported levels ever in 2017, when they were at 2·7%. The global average age increased from 26·6 years in 1950 to 32·1 years in 2017, and the proportion of the population that is of working age (age 15–64 years) increased from 59·9% to 65·3%. At the national level, the TFR decreased in all countries and territories between 1950 and 2017; in 2017, TFRs ranged from a low of 1·0 livebirths (95% UI 0·9–1·2) in Cyprus to a high of 7·1 livebirths (6·8–7·4) in Niger. The TFR under age 25 years (TFU25; number of livebirths expected by age 25 years for a hypothetical woman who survived the age group and was exposed to current ASFRs) in 2017 ranged from 0·08 livebirths (0·07–0·09) in South Korea to 2·4 livebirths (2·2–2·6) in Niger, and the TFR over age 30 years (TFO30; number of livebirths expected for a hypothetical woman ageing from 30 to 54 years who survived the age group and was exposed to current ASFRs) ranged from a low of 0·3 livebirths (0·3–0·4) in Puerto Rico to a high of 3·1 livebirths (3·0–3·2) in Niger. TFO30 was higher than TFU25 in 145 countries and territories in 2017. 33 countries had a negative population growth rate from 2010 to 2017, most of which were located in central, eastern, and western Europe, whereas population growth rates of more than 2·0% were seen in 33 of 46 countries in sub-Saharan Africa. In 2017, less than 65% of the national population was of working age in 12 of 34 high-income countries, and less than 50% of the national population was of working age in Mali, Chad, and Niger. Interpretation: Population trends create demographic dividends and headwinds (ie, economic benefits and detriments) that affect national economies and determine national planning needs. Although TFRs are decreasing, the global population continues to grow as mortality declines, with diverse patterns at the national level and across age groups. To our knowledge, this is the first study to provide transparent and replicable estimates of population and fertility, which can be used to inform decision making and to monitor progress. Funding: Bill & Melinda Gates Foundation.
|
|
| 9. |
- Micah, Angela E., et al.
(författare)
-
Tracking development assistance for health and for COVID-19 : a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050
- 2021
-
Ingår i: The Lancet. - : Elsevier. - 0140-6736 .- 1474-547X. ; 398:10308, s. 1317-1343
-
Forskningsöversikt (refereegranskat)abstract
- Background The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We aimed to put development assistance for health for COVID-19 in the context of broader trends in global health financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020. Methods We estimated domestic health spending and development assistance for health to generate total health-sector spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure Database to produce estimates of domestic health spending. To generate estimates for development assistance for health, we relied on project-level disbursement data from the major international development agencies' online databases and annual financial statements and reports for information on income sources. To adjust our estimates for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ per capita, purchasing-power parity-adjusted US$ per capita, and as a proportion of gross domestic product. We used various models to generate future health spending to 2050. Findings In 2019, health spending globally reached $8. 8 trillion (95% uncertainty interval [UI] 8.7-8.8) or $1132 (1119-1143) per person. Spending on health varied within and across income groups and geographical regions. Of this total, $40.4 billion (0.5%, 95% UI 0.5-0.5) was development assistance for health provided to low-income and middle-income countries, which made up 24.6% (UI 24.0-25.1) of total spending in low-income countries. We estimate that $54.8 billion in development assistance for health was disbursed in 2020. Of this, $13.7 billion was targeted toward the COVID-19 health response. $12.3 billion was newly committed and $1.4 billion was repurposed from existing health projects. $3.1 billion (22.4%) of the funds focused on country-level coordination and $2.4 billion (17.9%) was for supply chain and logistics. Only $714.4 million (7.7%) of COVID-19 development assistance for health went to Latin America, despite this region reporting 34.3% of total recorded COVID-19 deaths in low-income or middle-income countries in 2020. Spending on health is expected to rise to $1519 (1448-1591) per person in 2050, although spending across countries is expected to remain varied. Interpretation Global health spending is expected to continue to grow, but remain unequally distributed between countries. We estimate that development organisations substantially increased the amount of development assistance for health provided in 2020. Continued efforts are needed to raise sufficient resources to mitigate the pandemic for the most vulnerable, and to help curtail the pandemic for all. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.
|
|
| 10. |
- Bhat, P. Narayana, et al.
(författare)
-
THE THIRD FERMI GBM GAMMA-RAY BURST CATALOG : THE FIRST SIX YEARS
- 2016
-
Ingår i: Astrophysical Journal Supplement Series. - : Institute of Physics Publishing (IOPP). - 0067-0049 .- 1538-4365. ; 223:2
-
Tidskriftsartikel (refereegranskat)abstract
- Since its launch in 2008, the Fermi Gamma-ray Burst Monitor (GBM) has triggered and located on average approximately two.-ray bursts (GRBs) every three days. Here, we present the third of a series of catalogs of GRBs detected by GBM, extending the second catalog by two more years through the middle of 2014 July. The resulting list includes 1405 triggers identified as GRBs. The intention of the GBM GRB catalog is to provide information to the community on the most important observables of the GBM-detected GRBs. For each GRB, the location and main characteristics of the prompt emission, the duration, peak flux, and fluence are derived. The latter two quantities are calculated for the 50-300 keV energy band where the maximum energy release of GRBs in the instrument reference system is observed, and also for a broader energy band from 10 to 1000 keV, exploiting the full energy range of GBM's low-energy [NaI[Tl)] detectors. Using statistical methods to assess clustering, we find that the hardness and duration of GRBs are better fit by a two-component model with short-hard and long-soft bursts than by a model with three components. Furthermore, information is provided on the settings and modifications of the triggering criteria and exceptional operational conditions during years five and six in the mission. This third catalog is an official product of the Fermi GBM science team, and the data files containing the complete results are available from the High-Energy Astrophysics Science Archive Research Center.
|
|
| 11. |
- Fischer, Andreas, et al.
(författare)
-
1-(4-Methoxyphenyl)-5-phenylpenta-2,4-dien-1-one
- 2007
-
Ingår i: Acta Crystallographica Section E. - : International Union of Crystallography (IUCr). - 1600-5368. ; 63, s. O3540-U3779
-
Tidskriftsartikel (refereegranskat)abstract
- The title compound, C18H16O2, was prepared using literature procedures and crystallized from an acetone-toluene solution (50:50 v/v). The dihedral angle between the two aromatic rings is 9.28 (8) angstrom. The crystal packing is stabilized by van der Waals forces.
|
|
| 12. |
- Fischer, Andreas, et al.
(författare)
-
1-(4-Methylphenyl)-5-phenylpenta-2,4dien-1-one
- 2007
-
Ingår i: Acta Crystallographica Section E. - : International Union of Crystallography (IUCr). - 1600-5368. ; 63, s. O2832-U2003
-
Tidskriftsartikel (refereegranskat)abstract
- The title compound, C18H16O, features two conjugate double bonds, both in E conformations. The molecule is essentially planar: the dihedral angle between the two phenyl groups is 9.4 ( 1)degrees.
|
|
| 13. |
|
|
| 14. |
- Ghosh, Swagatha, 1987, et al.
(författare)
-
Modulation of biliverdin dynamics and spectral properties by Sandercyanin
- 2022
-
Ingår i: RSC Advances. - : Royal Society of Chemistry (RSC). - 2046-2069. ; 12:31, s. 20296-20304
-
Tidskriftsartikel (refereegranskat)abstract
- Biliverdin IX-alpha (BV), a tetrapyrrole, is found ubiquitously in most living organisms. It functions as a metabolite, pigment, and signaling compound. While BV is known to bind to diverse protein families such as heme-metabolizing enzymes and phytochromes, not many BV-bound lipocalins (ubiquitous, small lipid-binding proteins) have been studied. The molecular basis of binding and conformational selectivity of BV in lipocalins remains unexplained. Sandercyanin (SFP)-BV complex is a blue lipocalin protein present in the mucus of the Canadian walleye (Stizostedion vitreum). In this study, we present the structures and binding modes of BV to SFP. Using a combination of designed site-directed mutations, X-ray crystallography, UV/VIS, and resonance Raman spectroscopy, we have identified multiple conformations of BV that are stabilized in the binding pocket of SFP. In complex with the protein, these conformers generate varied spectroscopic signatures both in their absorption and fluorescence spectra. We show that despite no covalent anchor, structural heterogeneity of the chromophore is primarily driven by the D-ring pyrrole of BV. Our work shows how conformational promiscuity of BV is correlated to the rearrangement of amino acids in the protein matrix leading to modulation of spectral properties.
|
|
| 15. |
- Hokke, N H, et al.
(författare)
-
RF Information Harvesting for Medium Access in Event-driven Batteryless Sensing
- 2022
-
Ingår i: 2022 21st ACM/IEEE International Conference on Information Processing in Sensor Networks (IPSN). - : IEEE. - 9781665496247 - 9781665496254 ; , s. 377-389
-
Konferensbidrag (refereegranskat)abstract
- We present radio-frequency (RF) information harvesting, a channel sensing technique that takes advantage of the energy in the wireless medium to detect channel activity at essentially no energy cost. RF information harvesting is essential for event-driven wireless sensing applications using battery-less devices that harvest tiny amounts of energy from impromptu events, such as operating a switch, and then transmit the event notification to a one-hop gateway. As multiple such devices may concurrently detect events, coordinating access to the channel is key. RF information harvesting allows devices to break the symmetry between concurrently-transmitting devices based on the harvested energy from the ongoing transmissions. To demonstrate the benefits of RF information harvesting, we integrate it in a tailor-made ultra lowpower hardware MAC protocol we call Radio Frequency-Distance Packet Queuing (RF-DiPaQ). We build a hardware/software prototype of RF-DiPaQ and use an established Markov framework to study its performance at scale. Comparing RF-DiPaQ against staple contention-based MAC protocols, we show that it outperforms pure Aloha and 1-CSMA by factors of 3.55 and 1.21 respectively in throughput, while it saturates at more than double the offered load compared to 1-CSMA. As traffic increases, the energy saving of RF-DiPaQ against CSMA protocols increases, consuming 36% less energy than np-CSMA at typical offered loads.
|
|
| 16. |
- Yu, Hoi-Fung, et al.
(författare)
-
Synchrotron cooling in energetic gamma-ray bursts observed by the Fermi Gamma-Ray Burst Monitor
- 2015
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 573
-
Tidskriftsartikel (refereegranskat)abstract
- Context. We study the time-resolved spectral properties of energetic gamma-ray bursts (GRBs) with good high-energy photon statistics observed by the Gamma-Ray Burst Monitor ((IBM) onboard the Fermi Gamma-Ray Space Telescope. Aims. We aim to constrain in detail the spectral properties of GRB prompt emission on a time-resolved basis and to discuss the theoretical implications of the fitting results in the context of various prompt emission models. Methods. Our sample comprises eight GRBs observed by the Fermi (IBM in its first five years of mission, with 1 keV-1 MeV fluence f > 1.0 x 10(-4) erg cm(-2) and a signal-to-noise ratio level of S/N >= 10.0 above 900 keV. We performed a time-resolved spectral analysis using a variable temporal binning technique according to optimal S/N criteria, resulting in a total of 299 time-resolved spectra. We performed Band function fits to all spectra and obtained the distributions for the low-energy power-lay index alpha, the high-energy power-law index beta, the peak energy in the observed nu F-nu, spectrum E-p, and the difference between the low- and high-energy power-law indices Delta s = alpha-beta. We also applied a physically motivated synchrotron model, which is a triple power-law with constrained power-law indices and a blackbody component, to test the prompt emission for consistency with a synchrotron origin and obtain the distributions for the two break energies E-b,E-1 and E-b,E-2 the middle segment power-law index beta, and the Planck function temperature kT. Results. The Band function parameter distributions are alpha = -0.73(-0.21)(+0.16), beta = -2.13(-0.56)(+0.28), E-p = 374.47(-187.7)(+307.3) keV (log(10) E-p = 2.577(-0.30)(+0.26)), and Delta s = 1.38(-0.31)(+0.54), with average errors sigma(alpha) similar to 0.1, sigma(beta) similar to 0.2, and sigma(Ep) similar to 0.1E(p). Using the distributions of Delta s and beta, the electron population index p is found to be consistent with the "moderately fast" scenario, in which fast- and slow-cooling scenarios cannot be distinguished. The physically motivated synchrotron-fitting function parameter distributions are E-b,E-1 = 129.6(-32.4)(+132.2) keV, E-b,E-2 = 631.4(-309.6)(+582) keV, beta = 1.721(-0.25)(+0.48), and kT = 10.4(-3.7)(+4.9) keV, with average errors sigma(beta) similar to 0.2, sigma E-b,E-1 similar to 0.1E(b,1), sigma E-b,E-2 similar to 0.4E(b,2,) and sigma(kT) similar to 0.1kT. This synchrotron function requires the synchrotron injection and cooling break (i.e., E-min and E-cool) to be close to each other within a factor of ten, often in addition to a Planck function. Conclusions. A synchrotron model is found that is consistent with most of the time-resolved spectra for eight energetic Fermi (IBM bursts with good high-energy photon statistics as long as both the cooling and injection break are included and the leftmost spectral slope is lifted either by including a thermal component or when an evolving magnetic field is accounted for.
|
|
| 17. |
- Abelev, Betty, et al.
(författare)
-
Measurement of prompt J/psi and beauty hadron production cross sections at mid-rapidity in pp collisions at root s=7 TeV
- 2012
-
Ingår i: Journal of High Energy Physics. - 1029-8479. ; :11
-
Tidskriftsartikel (refereegranskat)abstract
- The ALICE experiment at the LHC has studied J/psi production at mid-rapidity in pp collisions at root s = 7 TeV through its electron pair decay on a data sample corresponding to an integrated luminosity L-int = 5.6 nb(-1). The fraction of J/psi from the decay of long-lived beauty hadrons was determined for J/psi candidates with transverse momentum p(t) > 1,3 GeV/c and rapidity vertical bar y vertical bar < 0.9. The cross section for prompt J/psi mesons, i.e. directly produced J/psi and prompt decays of heavier charmonium states such as the psi(2S) and chi(c) resonances, is sigma(prompt J/psi) (p(t) > 1.3 GeV/c, vertical bar y vertical bar < 0.9) = 8.3 +/- 0.8(stat.) +/- 1.1 (syst.)(-1.4)(+1.5) (syst. pol.) mu b. The cross section for the production of b-hadrons decaying to J/psi with p(t) > 1.3 GeV/c and vertical bar y vertical bar < 0.9 is a sigma(J/psi <- hB) (p(t) > 1.3 GeV/c, vertical bar y vertical bar < 0.9) = 1.46 +/- 0.38 (stat.)(-0.32)(+0.26) (syst.) mu b. The results are compared to QCD model predictions. The shape of the p(t) and y distributions of b-quarks predicted by perturbative QCD model calculations are used to extrapolate the measured cross section to derive the b (b) over bar pair total cross section and d sigma/dy at mid-rapidity.
|
|
| 18. |
- Abelev, Betty, et al.
(författare)
-
Underlying Event measurements in pp collisions at root s=0.9 and 7 TeV with the ALICE experiment at the LHC
- 2012
-
Ingår i: Journal of High Energy Physics. - 1029-8479. ; :7
-
Tidskriftsartikel (refereegranskat)abstract
- We present measurements of Underlying Event observables in pp collisions at root s = 0 : 9 and 7 TeV. The analysis is performed as a function of the highest charged-particle transverse momentum p(T),L-T in the event. Different regions are defined with respect to the azimuthal direction of the leading (highest transverse momentum) track: Toward, Transverse and Away. The Toward and Away regions collect the fragmentation products of the hardest partonic interaction. The Transverse region is expected to be most sensitive to the Underlying Event activity. The study is performed with charged particles above three different p(T) thresholds: 0.15, 0.5 and 1.0 GeV/c. In the Transverse region we observe an increase in the multiplicity of a factor 2-3 between the lower and higher collision energies, depending on the track p(T) threshold considered. Data are compared to PYTHIA 6.4, PYTHIA 8.1 and PHOJET. On average, all models considered underestimate the multiplicity and summed p(T) in the Transverse region by about 10-30%.
|
|
| 19. |
- Aliko, A., et al.
(författare)
-
World Workshop on Oral Medicine VI: clinical implications of medication-induced salivary gland dysfunction
- 2015
-
Ingår i: Oral Surgery Oral Medicine Oral Pathology Oral Radiology. - : Elsevier BV. - 2212-4403. ; 120:2, s. 185-206
-
Tidskriftsartikel (refereegranskat)abstract
- Objective. This study aimed to systematically review the available literature on the clinical implications of medication-induced salivary gland dysfunction (MISGD). Study Design. The systematic review was performed using PubMed, Embase, and Web of Science (through June 2013). Studies were assessed for degree of relevance and strength of evidence, based on whether clinical implications of MISGD were the primary study outcomes, as well as on the appropriateness of study design and sample size. Results. For most purported xerogenic medications, xerostomia was the most frequent adverse effect. In the majority of the 129 reviewed papers, it was not documented whether xerostomia was accompanied by decreased salivary flow. Incidence and prevalence of medication-induced xerostomia varied widely and was often associated with number and dose of medications. Xerostomia was most frequently reported to be mild-to-moderate in severity. Its onset occurred usually in the first weeks of treatment. There was selected evidence that medication-induced xerostomia occurs more frequently in women and older adults and that MISGD may be associated with other clinical implications, such as caries or oral mucosal alterations. Conclusions. The systematic review showed that MISGD constitutes a significant burden in many patients and may be associated with important negative implications for oral health.
|
|
| 20. |
- Dawes, C., et al.
(författare)
-
The functions of human saliva: A review sponsored by the World Workshop on Oral Medicine VI
- 2015
-
Ingår i: Archives of Oral Biology. - : Elsevier BV. - 0003-9969. ; 60:6, s. 863-874
-
Forskningsöversikt (refereegranskat)abstract
- This narrative review of the functions of saliva was conducted in the PubMed, Embase and Web of Science databases. Additional references relevant to the topic were used, as our key words did not generate references which covered all known functions of saliva. These functions include maintaining a moist oral mucosa which is less susceptible to abrasion, and removal of micro-organisms, desquamated epithelial cells, leucocytes and food debris by swallowing. The mucins form a slimy coating on all surfaces in the mouth and act as a lubricant during such processes as mastication, formation of a food bolus, swallowing and speaking. Saliva provides the fluid in which solid tastants may dissolve and distributes tastants around the mouth to the locations of the taste buds. The hypotonic unstimulated saliva facilitates taste recognition. Salivary amylase is involved in digestion of starches. Saliva acts as a buffer to protect oral, pharyngeal and oesophageal mucosae from orally ingested acid or acid regurgitated from the stomach. Saliva protects the teeth against acid by contributing to the acquired enamel pellicle, which forms a renewable lubricant between opposing tooth surfaces, by being supersaturated with respect to tooth mineral, by containing bicarbonate as a buffer and urea and by facilitating clearance of acidic materials from the mouth. Saliva contains many antibacterial, antiviral and antifungal agents which modulate the oral microbial flora in different ways. Saliva also facilitates the healing of oral wounds. Clearly, saliva has many functions which are needed for proper protection and functioning of the human body. (C) 2015 Elsevier Ltd. All rights reserved. RAMS CK, 1988, GASTROENTEROLOGY, V95, P1460
|
|
| 21. |
- Fischer, Andreas, et al.
(författare)
-
(2E)-3-(biphenyl-4-yl)-1-(2,4-dichlorophenyl)-prop-2-en-1-one
- 2007
-
Ingår i: Acta Crystallographica Section E. - : International Union of Crystallography (IUCr). - 1600-5368. ; 63, s. o1351-o1352
-
Tidskriftsartikel (refereegranskat)abstract
- The title compound, C21H14Cl2O, was prepared from biphenyl-4-carbaldehyde and 2,4-dichloroacetophenone. Single crystals were obtained from acetone. The compound crystallizes with four molecules in the asymmetric unit, all of which deviate significantly from planarity.
|
|
| 22. |
- Fischer, Andreas, et al.
(författare)
-
(2E)-3-(biphenyl-4-yl)-1-(4-bromophenyl)-prop-2-en-1-one
- 2007
-
Ingår i: Acta Crystallographica Section E. - : International Union of Crystallography (IUCr). - 1600-5368. ; 63, s. o1355-o1356
-
Tidskriftsartikel (refereegranskat)abstract
- The title compound, C21H15BrO, was obtained from 4-bromoacetophenone and biphenyl-4-carbaldehyde. The geometry of the molecule is unexceptional. The compound crystallizes isostructurally with the corresponding chloro compound.
|
|
| 23. |
- Fischer, Andreas, et al.
(författare)
-
(2E)-3-(biphenyl-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one
- 2007
-
Ingår i: Acta Crystallographica Section E. - : International Union of Crystallography (IUCr). - 1600-5368. ; 63, s. o1353-o1354
-
Tidskriftsartikel (refereegranskat)abstract
- The title compound, C21H15ClO, was prepared from biphenyl-4-carbaldehyde and 4-chloroacetophenone. Single crystals were obtained from acetone. The compound is isostructural with the corresponding Br compound. The molecule deviates significantly from planarity.
|
|
| 24. |
- Fischer, Andreas, et al.
(författare)
-
(2E)-3-(biphenyl-4-yl)-1-(4-methoxyphenyl)-prop-2-en-1-one
- 2007
-
Ingår i: Acta Crystallographica Section E. - : International Union of Crystallography (IUCr). - 1600-5368. ; 63, s. o1349-o1350
-
Tidskriftsartikel (refereegranskat)abstract
- The title compound, C22H18O2, was prepared from biphenyl-4-carbaldehyde and 4-methoxyacetophenone. The molecule deviates significantly from planarity.
|
|
| 25. |
- Fischer, Andreas, et al.
(författare)
-
(2E)-3-(biphenyl-4-yl)-1-phenylprop-2-en-1-one
- 2007
-
Ingår i: Acta Crystallographica Section E. - : International Union of Crystallography (IUCr). - 1600-5368. ; 63, s. o1357-o1358
-
Tidskriftsartikel (refereegranskat)abstract
- The title compound, C21H16O, was prepared from biphenyl-4-carbaldehyde and acetophenone. The molecule is essentially planar.
|
|
| 26. |
|
|
| 27. |
- Fischer, Andreas, et al.
(författare)
-
(8RS,9SR)-Ethyl4-(3-bromothien-2-yl)-6(2-furyl)-2-oxocyclohex-3-ene-1-carboxylate
- 2007
-
Ingår i: Acta Crystallographica Section E. - : International Union of Crystallography (IUCr). - 1600-5368. ; 63, s. O254-O255
-
Tidskriftsartikel (refereegranskat)abstract
- The title compound, C17H15BrO4S, was synthesized from (2E)1-(3-bromo-2-thienyl)-3-(2-furyl)prop-2-en-1-one and ethyl acetoacetate in an ethanol solution. Single crystals were obtained from an ethyl acetate/hexane mixture. The crystal packing is stabilized by van der Waals forces.
|
|
| 28. |
- Fischer, Andreas, et al.
(författare)
-
Ethyl 4-(3-bromo-2-thienyl)-2-oxo-6-phenylcyclohex-3-ene-1-carboxylate
- 2008
-
Ingår i: Acta Crystallographica Section E. - : International Union of Crystallography (IUCr). - 1600-5368. ; 64, s. O560-U861
-
Tidskriftsartikel (refereegranskat)abstract
- The title compound, C19H17BrO3S, crystallizes with two molecules in the asymmetric unit. The methyl group of one molecule is disordered approximately equally over two positions. The dihedral angles between the thiophene and phenyl groups are 68.5 (2) and 67.5 (2)degrees in the two molecules.
|
|
| 29. |
- Fischer, Andreas, et al.
(författare)
-
rac-Ethyl 3-(3-bromo-2-thienyl)-2-oxo-6-(4-propoxyphenyl)cyclohex-3-ene-1-carboxyl ate
- 2008
-
Ingår i: Acta Crystallographica Section E. - : International Union of Crystallography (IUCr). - 1600-5368. ; 64, s. O2152-U2248
-
Tidskriftsartikel (refereegranskat)abstract
- The racemic title compound, C22H23BrO4S, crystallizes with two molecules in the asymmetric unit. The dihedral angles between the thiophene and phenyl rings are 71.64 (17) and 73.41 (17)degrees.
|
|
| 30. |
|
|
| 31. |
- Jayaramulu, K., et al.
(författare)
-
Covalent Graphene-MOF Hybrids for High-Performance Asymmetric Supercapacitors
- 2021
-
Ingår i: Advanced Materials. - : Wiley-VCH Verlag. - 0935-9648 .- 1521-4095. ; 33:4
-
Tidskriftsartikel (refereegranskat)abstract
- In this work, the covalent attachment of an amine functionalized metal-organic framework (UiO-66-NH2 = Zr6O4(OH)4(bdc-NH2)6; bdc-NH2 = 2-amino-1,4-benzenedicarboxylate) (UiO-Universitetet i Oslo) to the basal-plane of carboxylate functionalized graphene (graphene acid = GA) via amide bonds is reported. The resultant GA@UiO-66-NH2 hybrid displayed a large specific surface area, hierarchical pores and an interconnected conductive network. The electrochemical characterizations demonstrated that the hybrid GA@UiO-66-NH2 acts as an effective charge storing material with a capacitance of up to 651 F g−1, significantly higher than traditional graphene-based materials. The results suggest that the amide linkage plays a key role in the formation of a π-conjugated structure, which facilitates charge transfer and consequently offers good capacitance and cycling stability. Furthermore, to realize the practical feasibility, an asymmetric supercapacitor using a GA@UiO-66-NH2 positive electrode with Ti3C2TX MXene as the opposing electrode has been constructed. The cell is able to deliver a power density of up to 16 kW kg−1 and an energy density of up to 73 Wh kg−1, which are comparable to several commercial devices such as Pb-acid and Ni/MH batteries. Under an intermediate level of loading, the device retained 88% of its initial capacitance after 10 000 cycles. © 2020 The Authors. Advanced Materials published by Wiley-VCH GmbH
|
|
| 32. |
- Karthigeyan, Dhanasekaran, et al.
(författare)
-
SERS and MD simulation studies of a kinase inhibitor demonstrate the emergence of a potential drug discovery tool
- 2014
-
Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : Proceedings of the National Academy of Sciences. - 0027-8424 .- 1091-6490. ; 111:29, s. 10416-10421
-
Tidskriftsartikel (refereegranskat)abstract
- We demonstrate the use of surface-enhanced Raman spectroscopy (SERS) as an excellent tool for identifying the binding site of small molecules on a therapeutically important protein. As an example, we show the specific binding of the common antihypertension drug felodipine to the oncogenic Aurora A kinase protein via hydrogen bonding interactions with Tyr-212 residue to specifically inhibit its activity. Based on SERS studies, molecular docking, molecular dynamics simulation, biochemical assays, and point mutation-based validation, we demonstrate the surface-binding mode of this molecule in two similar hydrophobic pockets in the Aurora A kinase. These binding pockets comprise the same unique hydrophobic patches that may aid in distinguishing human Aurora A versus human Aurora B kinase in vivo. The application of SERS to identify the specific interactions between small molecules and therapeutically important proteins by differentiating competitive and noncompetitive inhibition demonstrates its ability as a complementary technique. We also present felodipine as a specific inhibitor for oncogenic Aurora A kinase. Felodipine retards the rate of tumor progression in a xenografted nude mice model. This study reveals a potential surface pocket that may be useful for developing small molecules by selectively targeting the Aurora family kinases.
|
|
| 33. |
- Li, Haoyuan, et al.
(författare)
-
Diffraction data from aerosolized Coliphage PR772 virus particles imaged with the Linac Coherent Light Source
- 2020
-
Ingår i: Scientific Data. - : NATURE RESEARCH. - 2052-4463. ; 7:1
-
Tidskriftsartikel (refereegranskat)abstract
- Single Particle Imaging (SPI) with intense coherent X-ray pulses from X-ray free-electron lasers (XFELs) has the potential to produce molecular structures without the need for crystallization or freezing. Here we present a dataset of 285,944 diffraction patterns from aerosolized Coliphage PR772 virus particles injected into the femtosecond X-ray pulses of the Linac Coherent Light Source (LCLS). Additional exposures with background information are also deposited. The diffraction data were collected at the Atomic, Molecular and Optical Science Instrument (AMO) of the LCLS in 4 experimental beam times during a period of four years. The photon energy was either 1.2 or 1.7keV and the pulse energy was between 2 and 4 mJ in a focal spot of about 1.3 mu m x 1.7 mu m full width at half maximum (FWHM). The X-ray laser pulses captured the particles in random orientations. The data offer insight into aerosolised virus particles in the gas phase, contain information relevant to improving experimental parameters, and provide a basis for developing algorithms for image analysis and reconstruction.
|
|
| 34. |
- Narayana, S., et al.
(författare)
-
LOCI : privacy-aware, device-free, low-power localization of multiple persons using IR sensors
- 2020
-
Ingår i: Proceedings - 2020 19th ACM/IEEE International Conference on Information Processing in Sensor Networks, IPSN 2020. - : Institute of Electrical and Electronics Engineers Inc.. - 9781728154978 - 9781728154985 ; , s. 121-132
-
Konferensbidrag (refereegranskat)abstract
- High accuracy and device-free indoor localization is still a holy grail to enable smart environments. With the growing privacy concerns and regulations, it is necessary to develop methods and systems that can be low-power, device-free as well as privacy-aware. While IR-based solutions fit the bill, they require many modules to be installed in the area of interest for higher accuracy, or proper planning during installation, or they may not work if the background has multiple heat-emitting objects, etc. In this paper, we propose a custom-built miniature device called LOCI that uses IR sensing. One unit of LOCI can provide three-dimensional localization at best. LOCI uses only a thermopile and a PIR sensor built within a 5x5x2 cm3 module. Since IR-based sensing is used, LOCI consumes around 80 mW. LOCI uses analog waveform from the PIR sensor with the gain of the PIR sensor dynamically controlled through software in real-time to simulate spatial diversity. LOCI proposes low-complexity techniques with sensor fusion to eliminate the noise in the background, which has not been handled in previous works even with sophisticated signal processing techniques. Since LOCI uses raw data from the thermopile, the computations are power-efficient. We present the complete design of LOCI and the proposed methodology to estimate height and location. LOCI achieves accuracies of sub-22 cm with a confidence of 0.5 and sub-35 cm with a confidence of 0.8. The best-case location accuracy is 12.5 cm. The accuracy of height estimation is within 8 cm in majority cases. LOCI can easily be extended to recognize activities.
|
|
| 35. |
- Villa, A., et al.
(författare)
-
World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction
- 2016
-
Ingår i: Oral Diseases. - : Wiley. - 1354-523X. ; 22:5, s. 365-382
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of this paper was to perform a systematic review of the pathogenesis of medication-induced salivary gland dysfunction (MISGD). Review of the identified papers was based on the standards regarding the methodology for systematic reviews set forth by the World Workshop on Oral Medicine IV and the PRISMA statement. Eligible papers were assessed for both the degree and strength of relevance to the pathogenesis of MISGD as well as on the appropriateness of the study design and sample size. A total of 99 papers were retained for the final analysis. MISGD in human studies was generally reported as xerostomia (the sensation of oral dryness) without measurements of salivary secretion rate. Medications may act on the central nervous system (CNS) and/or at the neuroglandular junction on muscarinic, α-and β-adrenergic receptors and certain peptidergic receptors. The types of medications that were most commonly implicated for inducing salivary gland dysfunction were those acting onthe nervous, cardiovascular, genitourinary, musculoskeletal, respiratory, and alimentary systems. Although many medications may affect the salivary flow rate and composition, most of the studies considered only xerostomia. Thus, further human studies are necessary to improve our understanding of the association between MISGD and the underlying pathophysiology. © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
|
|
| 36. |
- Villa, A., et al.
(författare)
-
World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment
- 2015
-
Ingår i: Clinical Oral Investigations. - : Springer Science and Business Media LLC. - 1432-6981 .- 1436-3771. ; 19:7, s. 1563-1580
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives Medication-induced salivary gland dysfunction (MISGD) causes significant morbidity resulting in decreased quality of life. This systematic review assessed the literature on the prevalence, diagnosis, treatment, and prevention of MISGD. Materials and methods Electronic databases were searched for articles related to MISGD through June 2013. Four independent reviewers extracted information regarding study design, study population, interventions, outcomes, and conclusions for each article. Only papers with acceptable degree of relevance, quality of methodology, and strength of evidence were retained for further analysis. Results There were limited data on the epidemiology of MISGD. Furthermore, various methods were used to assess salivary flow rate or xerostomia. Preventive and therapeutic strategies included substitution of medications, oral, or systemic therapy with sialogogues, use of saliva substitutes or of electro-stimulating devices. Although there are promising approaches to improve salivary gland function, most studies are characterized by small numbers and heterogeneous methods. Conclusions Physicians and dentists should identify the medications associated with xerostomia and salivary gland dysfunction through a thorough medical history. Preferably, health care providers should measure the unstimulated and stimulated whole salivary flow rates of all their patients so that these values can be used as a baseline to rate the complaints of patients who subsequently claim to experience xerostomia or salivary gland dysfunction as well as the possibilities of effectively treating this condition. Clinical relevance MISGD remains a major burden for the population. This systematic review provides a contemporary in-depth description of the diagnosis and treatment of MISGD.
|
|
| 37. |
- Wolff, A., et al.
(författare)
-
A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI
- 2017
-
Ingår i: Drugs in R&D. - : Springer Science and Business Media LLC. - 1174-5886 .- 1179-6901. ; 17:1, s. 1-28
-
Tidskriftsartikel (refereegranskat)abstract
- Background Medication-induced salivary gland dysfunction (MISGD), xerostomia (sensation of oral dryness), and subjective sialorrhea cause significant morbidity and impair quality of life. However, no evidence-based lists of the medications that cause these disorders exist. Objective Our objective was to compile a list of medications affecting salivary gland function and inducing xerostomia or subjective sialorrhea. Data Sources Electronic databases were searched for relevant articles published until June 2013. Of 3867 screened records, 269 had an acceptable degree of relevance, quality of methodology, and strength of evidence. We found 56 chemical substances with a higher level of evidence and 50 with a moderate level of evidence of causing the abovementioned disorders. At the first level of the Anatomical Therapeutic Chemical (ATC) classification system, 9 of 14 anatomical groups were represented, mainly the alimentary, cardiovascular, genitourinary, nervous, and respiratory systems. Management strategies include substitution or discontinuation of medications whenever possible, oral or systemic therapy with sialogogues, administration of saliva substitutes, and use of electro-stimulating devices. Limitations While xerostomia was a commonly reported outcome, objectively measured salivary flow rate was rarely reported. Moreover, xerostomia was mostly assessed as an adverse effect rather than the primary outcome of medication use. This study may not include some medications that could cause xerostomia when administered in conjunction with others or for which xerostomia as an adverse reaction has not been reported in the literature or was not detected in our search. Conclusions We compiled a comprehensive list of medications with documented effects on salivary gland function or symptoms that may assist practitioners in assessing patients who complain of dry mouth while taking medications. The list may also prove useful in helping practitioners anticipate adverse effects and consider alternative medications.
|
|
| 38. |
- Wolinsky, JS, et al.
(författare)
-
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide
- 2013
-
Ingår i: Multiple sclerosis (Houndmills, Basingstoke, England). - : SAGE Publications. - 1477-0970 .- 1352-4585. ; 19:10, s. 1310-1319
-
Tidskriftsartikel (refereegranskat)abstract
- The purpose of this study was to determine the effects of oral teriflunomide on multiple sclerosis (MS) pathology inferred by magnetic resonance imaging (MRI). Methods: Patients ( n=1088) with relapsing MS were randomized to once-daily teriflunomide 7 mg or 14 mg, or placebo, for 108 weeks. MRI was recorded at baseline, 24, 48, 72 and 108 weeks. Annualized relapse rate and confirmed progression of disability (sustained ≥12 weeks) were the primary and key secondary outcomes. The principal MRI outcome was change in total lesion volume. Results: After 108 weeks, increase in total lesion volume was 67.4% ( p=0.0003) and 39.4% ( p=0.0317) lower in the 14 and 7 mg dose groups versus placebo. Other measures favoring teriflunomide were accumulated enhanced lesions, combined unique activity, T2-hyperintense and T1-hypointense component lesion volumes, white matter volume, and a composite MRI score; all were significant for teriflunomide 14 mg and most significant for 7 mg versus placebo. Conclusions: Teriflunomide provided benefits on brain MRI activity across multiple measures, with a dose effect evident on several markers. These effects were also consistent across selected subgroups of the study population. These findings complement clinical data showing significant teriflunomide-related reductions in relapse rate and disease progression, and demonstrate containment of MRI-defined disease progression.
|
|
